Single-agent efficacy of NKTR-214 compared with aldesleukin in... | Download Scientific Diagram
A Study of NKTR-214 for Participants With Previously Untreated Inoperable or Metastatic Melanoma - Associazione Melanoma Italia Onlus
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update | HTML
Immuno-oncology: Nektar Therapeutics and Alkermes present data
Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist | Nature Communications
![PDF] NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4b6d90c13629ffeaf1bdd2a19aa49043ea18b2f6/5-Figure2-1.png "PDF] NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models | Semantic Scholar")
PDF] NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models | Semantic Scholar
Nektar shows durability of Opdivo combo in 18-month update | Fierce Biotech
Parameterization of the mathematical model for NKTR-214 dynamics to... | Download Scientific Diagram
ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma
NKTR-214 delivers a controlled, sustained, and biased signal through... | Download Scientific Diagram
NKTR-214 delivers a controlled and sustained activation signal to the... | Download Scientific Diagram
![PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/ac84a0206049aa7de2ea3c0e7e3ec3f34d9e076f/1-Figure2-1.png "PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar")
PDF] PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors. | Semantic Scholar
JCM | Free Full-Text | Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update | HTML
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer | Journal for ImmunoTherapy of Cancer
Bristol/Nektar's Opdivo/NKTR-214 Combo Responses Deepen Over Time
IsoPlexis' Blood-Based Biomarker Predicts Progression-Free Survival in Melanoma Study | IsoPlexis
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy | PLOS ONE
Nektar Therapeutics Spotlight: Watch For NKTR-214 Results This Weekend At Society For Immunotherapy Of Cancer Annual Meeting (NASDAQ:NKTR) | Seeking Alpha
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer | Journal for ImmunoTherapy of Cancer
Pegging The Value Of NKTR-214 At Zero (NASDAQ:NKTR) | Seeking Alpha
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy | Nature Communications
NKTR-214-Opdivo Combo for Melanoma Earns FDA Breakthrough Status
Parameterization of the mathematical model for NKTR-214 dynamics to... | Download Scientific Diagram
ASCO GU 2019: PIVOT-02 Study of NKTR-214 with Nivolumab in Metastatic Urothelial Carcinoma
Nektar | Pipeline | Winter Congress Virtual Booth
